Occurrence of the malate-aspartate shuttle in various tumor types.
The activity of the malate-aspartate shuttle for the reoxidation of cytoplasmic reduced nicotinamide adenine dinucleotide (NADH) by mitochondria was assessed in six lines of rodent ascites tumor cells (two strains of Ehrlich ascites carcinoma, Krebs II carcinoma, Novikoff hepatoma, AS-30D hepatoma, and L1210 mouse leukemia). All the tumor cells examined showed mitochondrial reoxidation of cytoplasmic NADH, as evidenced by the accumulation of pyruvate when the cells were incubated aerobically with L-lactate. Reoxidation of cytoplasmic NADH thus generated was completely inhibited by the transaminase inhibitor aminooxyacetate. The involvement of the respiratory chain in the reoxidation of cytoplasmic NADH was demonstrated by the action of cyanide, rotenone, and antimycin A, which strongly inhibited the formation of pyruvate from added L-lactate. Compounds that inhibit the carrier-mediated entry of malate into mitochondria, such as butylmalonate, benzenetricarboxylate, and iodobenzylmalonate, also inhibited the accumulation of pyruvate from added L-lactate by the tumor cells. The maximal rate of the malate-aspartate shuttle was established by addtion of arsenite to inhibit the mitochondrial oxidation of the pyruvate formed from added lactate. The capacity of the various tumor lines for the reoxidation of cytoplasmic NADH via the malate-aspartate shuttle approaches 20% of the total respiratory rate of the cells and thus appears to be sufficient to account for the mitochondrial reoxidation of that fraction of glycolytic NADH not reoxidized by pyruvate and lactate dehydrognenase in the cytoplasm.
D000625:Aminooxyacetic Acid / Q000494:pharmacology; D000818:Animals; D000968:Antimycin A / Q000494:pharmacology; D001224:Aspartic Acid / Q000378:metabolism*; D002286:Carcinoma, Ehrlich Tumor / Q000378:metabolism; D006528:Carcinoma, Hepatocellular / Q000378:metabolism; D002287:Carcinoma, Krebs 2 / Q000378:metabolism; D002460:Cell Line; D003486:Cyanides / Q000494:pharmacology; D007700:Kinetics; D007773:Lactates / Q000378:metabolism; D007939:Leukemia L1210 / Q000378:metabolism; D008113:Liver Neoplasms; D008293:Malates / Q000378:metabolism*; D008314:Malonates / Q000494:pharmacology; D008928:Mitochondria / Q000378:metabolism; D009243:NAD / Q000378:metabolism; D009374:Neoplasms, Experimental / Q000378:metabolism*; D010084:Oxidation-Reduction; D011773:Pyruvates / Q000378:metabolism; D012402:Rotenone / Q000494:pharmacology; D014233:Tricarboxylic Acids / Q000494:pharmacology
D003486:Cyanides; D007773:Lactates; D008293:Malates; D008314:Malonates; D011773:Pyruvates; D014233:Tricarboxylic Acids; D012402:Rotenone; D009243:NAD; D000625:Aminooxyacetic Acid; D001224:Aspartic Acid; D000968:Antimycin A